Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
Pfizer starts voluntary withdraw of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
biznews.com16h
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
The Pharma Letter17h
The week in pharma: action, reaction and insight – week to September 27
Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...
health.economictimes.indiatimes23h
Why gene therapy for sickle cell is slow to catch on with patients
Gene Therapy: "It is so new ... I wanted to see more success stories before I committed to it," said Davis, who is studying ...